Toward Cannabinoid Use for Refractory Cutaneous Dermatomyositis

J Invest Dermatol. 2022 Oct;142(10):2556-2557. doi: 10.1016/j.jid.2022.07.017.
No abstract available

Publication types

  • Comment

MeSH terms

  • Administration, Cutaneous
  • Cannabinoids* / therapeutic use
  • Dermatomyositis* / drug therapy
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Skin

Substances

  • Cannabinoids
  • Immunoglobulins, Intravenous